5 Pandemic Stocks That Are Losing Value

In this article, we discuss 5 pandemic stocks that are losing value. If you want our detailed analysis of these stocks, go directly to 10 Pandemic Stocks That Are Losing Value. 

5. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 43

Loss in Share Price Over 6 Months as of March 1: 62.40%

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company that creates therapeutics and vaccines to treat infectious and rare diseases, immuno-oncology, cardiovascular diseases, and autoimmune diseases. The stock exploded when Moderna, Inc. (NASDAQ:MRNA) created the COVID-19 vaccine that became one of the four WHO approved vaccines for the pandemic. 

Moderna, Inc. (NASDAQ:MRNA) significantly declined in the last few months owing to the broad sell-off in growth stocks, and investors believe that the company has run its course with the COVID-19 vaccine gains. The stock also lost value when the U.S. Supreme Court ruled that the vaccine mandate for large companies by the Biden administration was unconstitutional.

Despite the stock underperforming over the last six months, Moderna, Inc. (NASDAQ:MRNA) reported above consensus earnings and revenue for the quarter ending December 2021. In Q4, 43 hedge funds were bullish on Moderna, Inc. (NASDAQ:MRNA), down from 49 funds in the prior quarter. Theleme Partners held the biggest stake in the company, with more than 5 million shares worth $1.27 billion. 

Here is what Carillon Tower Advisers has to say about Moderna, Inc. (NASDAQ:MRNA) in its Q3 2021 investor letter:

“Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The stock proved to be an impressive contributor once again in the quarter, as investors continue to evaluate the potential for future growth driven primarily by the firm’s revolutionary COVID-19 vaccine. Strong global demand for the vaccine may persist for the foreseeable future in order to maintain immunity as well as provide protection against any additional future variants. The potential for the firm’s mRNA technology to be used in a number of other use cases, specifically influenza, could also provide an additional tailwind for future growth.”